SOUTH SAN FRANCISCO, Calif., July 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will host a Key Opinion Leader meeting on the treatment of multi-drug resistant (MDR) infections at 8 a.m. Eastern Time on Tuesday, July 19 in New York City.
The meeting will feature a keynote presentation by renowned infectious disease expert Keith S. Kaye, M.D., M.P.H., who will discuss current approaches and novel therapies to treating MDR gram-negative bacterial infections. Members of the Achaogen executive management team will also provide an overview of and progress with the Company’s ongoing clinical development program with lead product candidate, plazomicin, which is currently being evaluated in two Phase 3 clinical trials for the treatment of serious bacterial infections that include MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE.
Dr. Keith S. Kaye is a Professor of Medicine in the Division of Infectious Diseases and Department of Medicine at Wayne State University and Detroit Medical Center. As the Corporate Vice President of Quality and Patient Safety, and the Corporate Medical Director of Hospital Epidemiology and Antimicrobial Stewardship at Detroit Medical Center and Wayne State University, Dr. Kaye oversees all Infection Prevention and Antibiotic Stewardship-related activities at the 8-hospital health system, which has over 2,000 beds and includes both community and tertiary care hospitals.
Dr. Kaye has been an international leader in infection prevention and antimicrobial stewardship. His particular interests and areas of expertise are the epidemiology of and outcomes associated with MDR bacteria, infections in the elderly, surgical site infection, device-related infections and antimicrobial stewardship. Dr. Kaye is currently a principal investigator on two multi-center NIH-funded clinical trials focusing on polymyxin-based therapy for infections due to extremely-drug resistant (XDR) gram-negative bacilli.
Dr. Kaye received his medical degree from the University of Pennsylvania. He completed a residency in Internal Medicine and a fellowship in Infectious Diseases at Beth Israel Deaconess Medical Center in Boston, Mass. During his fellowship, Dr. Kaye also earned a Masters in Public Health from the Harvard School of Public Health.
The event is intended for investors, sell-side analysts, and business development professionals only. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com to reserve a place.
A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20160719/reg.jsp and the Investors section of the Company’s website at http://investors.achaogen.com/events.cfm.
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.